MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML-007C-MA in adults with an acute exacerbation of schizophrenia met the primary endpoint at the twice-daily 210/3 mg dose. The once-daily 330/6 mg dose failed to achieve statistical significance on the primary endpoint, showing only numerical improvement over placebo.
Intraday volume topped 5.13 million shares, compared with the daily average of 413,234.
AiRWA (YYAI) agreed to buy Hongkong Best Life Trade for a base price of $50 million plus potential performance payouts.
The stock plunged 74% with volume topping 2.05 million shares, compared with the daily average of 19,642.
Nvidia (NVDA) agreed to expand its partnership with South Korean conglomerate SK Group through an AI infrastructure initiative valued at more than $500 billion.
Nvidia dropped 5% as volume topped 100.3 million shares, compared with the daily average of 154.5 million.
SK hynix (SKHY), part of the SK Group, fell 7.6% as volume topped 40.5 million shares, compared with the daily average of 55.5 million.
Price: $11.52, Change: $-25.04, Percent Change: -68.49%